Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ClearPoint Neuro, Inc.MRIC · Entity 2367 | Vice President, Marketing | October 04, 2017 | October 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ClearPoint Neuro, Inc.
Report date October 04, 2017 · Filed October 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,900 |
Reported balance
After 2017-10-04 transaction · row 1
1 source rowRow 1 · 2017-10-04 · Grant · Acquired 8,503 · Balance 38,900 F1: The Reporting Person received a portion of her 2016 cash bonus in the form of the Company's common stock based on the closing sales price of the Company's common stock on October 4, 2017. The shares were granted under the Company's Second Amended and Restated 2013 Incentive Compensation Plan. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2027-10-04 | Direct | 1,875 |
Reported balance
After 2017-10-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-04 · Grant · Acquired 1,875 · Balance 1,875 F2: The shares subject to this option vest ratably in three equal installments on December 1, 2017, December 1, 2018 and December 1, 2019. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2027-10-04 | Direct | 20,000 |
Reported balance
After 2017-10-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-04 · Grant · Acquired 20,000 · Balance 20,000 F3: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a monthly basis over the 24-month period immediately following the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received a portion of her 2016 cash bonus in the form of the Company's common stock based on the closing sales price of the Company's common stock on October 4, 2017. The shares were granted under the Company's Second Amended and Restated 2013 Incentive Compensation Plan.
F2: The shares subject to this option vest ratably in three equal installments on December 1, 2017, December 1, 2018 and December 1, 2019.
F3: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a monthly basis over the 24-month period immediately following the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2017 Filed Oct 5, 2017 16:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001534424-17-000415 · maners.xml · derivative · entry 3 Maners Wendelin C · CIK 0001490997 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-10-04 F3 · derivative.exercise_date: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a monthly basis over the 24-month period immediately following the first anniversary of the grant date. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 16:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantStock Options (right to buy) · Derivative | 1,875 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001534424-17-000415 · maners.xml · derivative · entry 2 Maners Wendelin C · CIK 0001490997 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2027-10-04 F2 · derivative.exercise_date: The shares subject to this option vest ratably in three equal installments on December 1, 2017, December 1, 2018 and December 1, 2019. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 16:11 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 8,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001534424-17-000415 · maners.xml · nonDerivative · entry 1 Maners Wendelin C · CIK 0001490997 · Vice President, Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,900 F1 · price: The Reporting Person received a portion of her 2016 cash bonus in the form of the Company's common stock based on the closing sales price of the Company's common stock on October 4, 2017. The shares were granted under the Company's Second Amended and Restated 2013 Incentive Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.